CGRP monoclonal antibodies: general aspects

Evidence-based neurology checklist on cgrp monoclonal antibodies: general aspects: Indications The CGRP mAbs are indicated for episodic or chronic migraine They provide sustained reductions in migraine headaches over 2 years They are usually indicated after the failure of ≥2 other prophylactic…

Indications

  • The CGRP mAbs are indicated for episodic or chronic migraine
  • They provide sustained reductions in migraine headaches over 2 years
  • They are usually indicated after the failure of ≥2 other prophylactic drugs
  • They may be considered in migraine with medication overuse headache
  • A recent guideline however recommends their use as first line prophylactic options

General contraindications

Administration

Precautions

General adverse effects

Management of non-responders

Acronym

References

  1. Hou M, Xing H, Cai Y, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 2017; 18:42.
  2. Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg 2017; 154: 74-78.
  3. Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 2017; 30:272-280. 
  4. Schuster NM, Rapoport AM. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review. Clin Neuropharmacol 2017; 40:169-174.
  5. Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 2017; 30:272-280.
  6. And 6 more. Subscribe to see the full list

Related checklists

Loading...